CEO Matthew Darin On Q4 Curaleaf Earnings

In this special episode of Trade To Black, we’ll be featuring a special guest: Matthew Darin, CEO of Curaleaf. Matthew Darin joins us to talk about Curaleaf’s recently released Q4 2023 results, plus some of the biggest events upcoming for the company. You won’t want to miss this interview.

Shadd Dales and Anthony Varrell catch up with Matthew Darin. It’s been a good three months since we last touched base closely with Curaleaf—around the time that they launched on the TSX. Darin believes the industry is on a strong trajectory, and we’ll get some of his thoughts on what lies ahead.

Looking at the earnings report: Curaleaf achieved record Q4 revenue of $345 million, which is a 4% rise from Q3. Their adjusted EBITDA for the quarter was $83 million, 24% of sales. Earnings per share was -0.01, above analyst’s estimates, and Curaleaf did report a net loss of $63 million for the quarter, with an adjusted net loss of $5 million. Darin, however, remains optimistic about future growth, particularly if any of the rumors begin to pan out.

Matthew Darin shares what he believes are some of the biggest opportunities that lie ahead. In the domestic market, including the US, there’s a few key markets about to kick off. Curaleaf plans to leverage that adult-use cannabis legalization happening in New York, Ohio, Florida, and Pennsylvania. There is a huge wholesale opportunity to be had.  Internationally, expansion into European markets is underway with a focus on Germany, the UK, and Poland.

Find out what some of the biggest drivers affecting their margins are, straight from the source. We’ll be diving deep into Curaleaf’s Q4 earnings, uncovering the strategies propelling the company forward. Discover how Curaleaf plans to sustain its growth trajectory and what exciting developments await in 2024. Don’t miss out on this exciting interview with Matthew Darin, Curaleaf CEO.

You might also like

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More